Amicus Therapeutics, Inc. (FOLD) earnings
FOLD earnings moved a median of -0.85% by the close. Quarterly and annual FOLD reports and results, each read against the price at its own news timestamp. Back to the FOLD overview →
24 measured FOLD earnings events.
Where these FOLD earnings landedvs 24 measured FOLD earnings reactions
| Middle 50% of FOLD earnings reactions | -2.59% to +0.80% |
|---|---|
| Median reaction (to close) | -0.85% |
| Measured reactions | 24 |
Point-in-time · zero look-ahead
Half of the 24 FOLD earnings events with a measured close landed between -2.59% and +0.80%; 33% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-K AMICUS THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | +0.14% | +0.21% | |
| Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates | Press release | +2.64% | -0.99% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | +2.21% | +1.55% | |
| Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 | Press release | -1.05% | -0.82% | |
| Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates | Press release | -0.95% | -4.77% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | +0.84% | +6.04% | |
| Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 | Press release | +0.32% | +0.83% | |
| Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates | Press release | +4.01% | +1.21% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | +0.22% | -0.30% | |
| Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 | Press release | -0.15% | -0.89% | |
| Form 10-K AMICUS THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -1.38% | -3.71% | |
| Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates | Press release | -5.52% | -10.08% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -1.42% | -2.31% | |
| Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 | Press release | -0.26% | -2.12% | |
| Amicus Therapeutics Announces Second Quarter 2024 Financial Results and Corporate Updates | Press release | -2.50% | +2.91% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | +0.88% | +0.79% | |
| Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024 | Press release | -1.29% | -0.20% | |
| Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates | Press release | -2.40% | -5.01% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | -0.58% | -2.84% | |
| Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024 | Press release | -0.59% | +3.37% | |
| Form 10-K AMICUS THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | -0.53% | -2.51% | |
| Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates | Press release | -3.24% | -0.61% | |
| Form 10-Q AMICUS THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | -4.93% | -12.19% | |
| Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023 | Press release | -0.28% | -1.20% |
Keep exploring
More FOLD: analyst actions → · SEC filings → · FOLD overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ARADIGM CORP COMMON STOCK (ARDM) | 384 | 0.00% | 39% |
| HISTOGENICS CORP COMMON (HSGX) | 383 | -0.30% | 35% |
| CORIUM INTL (CORI) | 380 | 0.00% | 46% |
| PROTEON THERAPEUTICS (PRTO) | 380 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.